Treatment of autoimmune liver disease: Current and future therapeutic options

Therapeutic Advances in Chronic Disease

Volumn 4, Issue 3, 2013, Pages 119-141

  Trivedi, Palak J ^a   Hirschfield, Gideon M ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Aetiology; Autoimmune hepatitis; Autoimmune liver disease; Pathogenesis; Primary biliary cirrhosis; Primary sclerosing cholangitis; Treatment

Indexed keywords

24 NORURSODEOXYCHOLIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BEZAFIBRATE; BUDESONIDE; CALCINEURIN INHIBITOR; CD80 ANTIBODY; COLCHICINE; CORTICOSTEROID; CXCL10 ANTIBODY; CYCLOSPORIN A; FARNESOID X RECEPTOR; FIBRIC ACID DERIVATIVE; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 23 ANTIBODY; MERCAPTOPURINE; METHOTREXATE; METRONIDAZOLE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OBETICHOLIC ACID; PLACEBO; PREDNISOLONE; PREDNISONE; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID DERIVATIVE; VASCULAR CELL ADHESION MOLECULE 1;

ADJUVANT THERAPY; ALTERNATIVE MEDICINE; ARTICLE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE LIVER DISEASE; BONE MARROW SUPPRESSION; CELL THERAPY; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; COLORECTAL CANCER; COLORECTAL DYSPLASIA; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPLASIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FIBROSIS; MOLECULAR THERAPY; MONOTHERAPY; NONHUMAN; PATIENT CODING; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; REGULATORY T LYMPHOCYTE; RELAPSE; REMISSION; SURVIVAL RATE; TOXIC HEPATITIS; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 84880420272     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622313478646     Document Type: Review

References (181)

1. Adams D. Eksteen B. Curbishley S. (2008) Immunology of the gut and liver: a love / hate relationship. Gut 57: 838–848.
2. Al Mamari S. Djordjevic J. Halliday J. Chapman R. (2012) Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 58: 329–334.
3. Almasio P. Floreani A. Chiaramonte M. Provenzano G. Battezzati P. Crosignani A. et al. (2000) Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis. Aliment Pharmacol Ther 14: 1645–1652.
4. Alvarez F. Ciocca M. Canero-Velasco C. Ramonet M. de Davila M. Cuarterolo M. et al. (1999) Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 30: 222–227.
5. Angulo P. Dickson E. Therneau T. Jorgensen R. Smith C. de Sotel C. et al. (1999) Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 30: 830–835.
6. Angulo P. Maor-Kendler Y. Lindor K. (2002) Small-duct primary sclerosing cholangitis: prevalence and natural history. Hepatology 35: 1494–1500.
7. Aqel B. Machicao V. Rosser B. Satyanarayana R. Harnois D. Dickson R. (2004) Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004; 38: 805–809.
8. Aw M. Dhawan A. Samyn M. Bargiota A. Mieli-Vergani G. (2009) Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 51: 156–160.
9. Baven-Pronk A. Coenraad M. van Buuren H. de Man R. van Erpecum K. Lamers M. et al. (2011) The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther 34: 335–343.
10. Benedetti A. Alvaro D. Bassotti C. Gigliozzi A. Ferretti G. La Rosa T. et al. (1997) Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver. Hepatology 26: 9–21.
11. Bergquist A. Ekbom A. Olsson R. Kornfeldt D. Lööf L. Danielsson A. et al. (2002) Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36: 321–327.
12. Bergquist A. Glaumann H. Persson B. Broome U. (1998) Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case–control study. Hepatology 27: 311–316.
13. Beuers U. Boberg K. Chapman R. Chazouillères O. Invernizzi P. Jones D. et al. (2009) EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 51: 237–267.
14. Beuers U. Spengler U. Kruis W. Aydemir U. Wiebecke B. Heldwein W. et al. (1992) Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo controlled trial. Hepatology 16: 707–714.
15. Björnsson E. Boberg K. Cullen S. Fleming K. Clausen O. Fausa O. et al. (2002) Patients with small duct primary sclerosing cholangitis have a favorable long-term prognosis. Gut 51: 731–735.
16. Björnsson E. Olsson R. Berquist A. Lindgren S. Braden B. Chapman R. et al. (2008) The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 134: 975–980.
17. Boberg K. Bergquist A. Mitchell S. Pares A. Rosina F. Broomé U. et al. (2002) Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 37: 1205–1211.
18. Bogdanos D. Komorowski L. (2011) Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta 412: 502–512.
19. Brandsaeter B. Isoniemi H. Broome U. Olausson M. Bäckman L. Hansen B. et al. (2004) Liver transplantation for primary sclerosing cholangitis: predictors and consequences of hepatobiliary malignancy. J Hepatol 40: 815–822.
20. Bressler B. Pinto R. El-Ashry D. Heathcote E. (2005) Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection? Gut 54: 407–410.
21. Broomé U. Glaumann H. Lindstöm E. Lööf L. Almer S. Prytz H. et al. (2002) Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol 36: 586–589.
22. Broomé U. Olsson R. Lööf L. Bodemar G. Hultcrantz R. Danielsson A. et al. (1996) Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38: 610–615.
23. Carpenter H. Czaja A. (2002) The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 6: 685–705.
24. Chapman M. Webster G. Bannoo S. Johnson G. Wittmann J. Pereira S. (2012) Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol 24: 1051–1058.
25. Chazouilleres O. Wendum D. Serfaty L. Rosmorduc O. Poupon R. (2006) Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 44: 400–406.
26. Christensen E. Crowe J. Doniach D. Popper H. Ranek L. Rodés J. et al. (1980) Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 78: 236–246.
27. Christensen E. Neuberger J. Crowe J. Altman D. Popper H. Portmann B. et al. (1985) Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 89: 1084–1091.
28. Chuang Y. Lian Z. Cheng C. Lan R. Yang G. Moritoki Y. et al. (2005) Increased levels of chemokine receptor CXCR 3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives. J Autoimmun 25: 126–132.
29. Combes B. Emerson S. Flye N. Munoz S. Luketic V. Mayo M. et al. (2005) Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 42: 1184–1193.
30. Corpechot C. Abenavoli L. Rabahi N. Chrétien Y. Andréani T. Johanet C. et al. (2008) Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48: 871–877.
31. Corpechot C. Carrat F. Bonnand A. Poupon R. Poupon R. (2000) The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 32: 1196–1199.
32. Corpechot C. Chazouillères O. Poupon R. (2011) Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome. J Hepatol 55: 1361–1367.
33. Cuarterolo M. Ciocca M. Velasco C. Ramonet M. González T. López S. et al. (2006) Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 43: 635–639.
34. Cullen S. Rust C. Fleming K. Edward C. Beuers U. Chapman R. (2008) High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 48: 792–800.
35. Czaja A. (2009 a) Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 29: 816–823.
36. Czaja A. (2009 b) Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 51: 161–167.
37. Czaja A. (2011) Autoimmune hepatitis in special patient populations. Best Pract Res Clin Gastroenterol 25: 689–700.
38. Czaja A. Carpenter H. (2003) Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 23: 116–123.
39. Czaja A. Carpenter H. Lindor K. (1999) Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 30: 1381–1386.
40. Czaja A. Lindor K. (2000) Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 119: 1312–1316.
41. Danielsson A. Prytz H. (1994) Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 8: 585–590.
42. Davies Y. Cox K. Abdullah B. Safta A. Terry A. Cox K. (2008) Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 47: 61–67.
43. Decock S. McGee P. Hirschfield G. (2009) Autoimmune liver disease for the non-specialist. BMJ 339: b3305.
44. de Groote J. Fevery J. Lepoutre L. (1978) Long-term follow-up of chronic active hepatitis of moderate severity. Gut 19: 510–513.
45. Dhaliwal H. Anderson R. Thornhill E. Schneider S. McFarlane E. Gleeson D. et al. (2012) Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis. Hepatology 56: 1401–1408.
46. Doyle A. Forbes G. Kontorinis N. (2011) Autoimmune hepatitis during infliximab therapy for Crohn's disease: a case report. J Crohns Colitis 5: 253–255.
47. Eaton J. Silveira M. Pardi D. Sinakos E. Kowdley K. Luketic V. et al. (2011) High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 106: 1638–1645.
48. Eaton J. Thackeray E. Lindor K. (2012) Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. Am J Gastroenterol 107: 431–439.
49. Farkkila M. Karvonen A. Nurmi H. Nuutinen H. Taavitsainen M. Pikkarainen P. et al. (2004) Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 40: 1379–1386.
50. Feld J. Dinh H. Arenovich T. Marcus V. Wanless I. Heathcote E. (2005) Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 42: 53–62.
51. Fickert P. Wagner M. Marschall H. Fuchsbichler A. Zollner G. Tsybrovskyy O. et al. (2006) 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr 2 (Abcb4) knockout mice. Gastroenterology 130: 465–481.
52. Fickert P. Zollner G. Fuchsbichler A. Stumptner C. Weiglein A. Lammert F. et al. (2002) Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr 2 knockout mice via disruption of cholangioles. Gastroenterology 123: 1238–1251.
53. Fiorucci S. Clerici C. Antonelli E. Orlandi S. Goodwin B. Sadeghpour B. et al. (2005) Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther 313: 604–612.
54. Gleeson D. Heneghan M. ; British Society of Gastroenterology (2011) British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 60: 1611–1629.
55. Goldenberg G. Jorizzo J. (2005) Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatol Treat 16: 347–349.
56. Gong Y. Huang Z. Christensen E. Gluud C. (2008) Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev (3): CD000551.
57. Goodyear O. Dennis M. Jilani N. Loke J. Siddique S. Ryan G. et al. (2012) Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 119: 3361–3369.
58. Gotthardt D. Rudolph G. Kloters-Plachky P. Kulaksiz H. Stiehl A. (2010) Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment. Gastrointest Endosc 71: 527–534.
59. Gregorio G. Portmann B. Karani J. Harrison P. Donaldson P. Vergani D. et al. (2001) Autoimmune hepatitis / sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 33: 544–553.
60. Habal F. Huang V. (2012) Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment Pharmacol Ther 35: 501–515.
61. Harnois D. Angulo P. Jorgensen R. Larusso N. Lindor K. (2001) High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 96: 1558–1562.
62. Heathcote J. Ross A. Sherlock S. (1976) A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology 70: 656–660.
63. Hempfling W. Grunhage F. Dilger K. Reichel C. Beuers U. Sauerbruch T. (2003) Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 38: 196–202.
64. Hennes E. Oo Y. Schramm C. Denzer U. Buggisch P. Wiegard C. et al. (2008) Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 103: 3063–3070.
65. Hintermann E. Bayer M. Pfeilschifter J. Luster A. Christen U. (2010) CXCL 10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation. J Autoimmun 35: 424–435.
66. Hirschfield G. Liu X. Xu C. Lu Y. Xie G. Lu Y. et al. (2009) Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 360: 2544–2555.
67. Hlivko J. Shiffman M. Stravitz R. Luketic V. Sanyal A. Fuchs M. et al. (2008) A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 6: 1036–1040.
68. Hoeroldt B. McFarlane E. Dube A. Basumani P. Karajeh M. Campbell M. et al. (2011) Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 140: 1980–1989.
69. Ichai P. Duclos-Vallee J. Guettier C. Hamida S. Antonini T. Delvart V. (2007) Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 13: 996–1003.
70. Imam M. Sinakos E. Gossard A. Kowdley K. Luketic V. Edwyn Harrison M. et al. (2011) High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther 34: 1185–1192.
71. Iwasaki S. Ohira H. Nishiguchi S. Zeniya M. Kaneko S. Onji M. et al. (2008) The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res 38: 557–564.
72. Jackson L. Song E. (1995) Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 36: 459–461.
73. Johnson P. McFarlane I. Williams R. (1995) Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 333: 958–963.
74. Jones D. Al-Rifai A. Frith J. Patanwala I. Newton J. (2010) The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up. J Hepatol 53: 911–917.
75. Kanda T. Yokosuka O. Imazeki F. (2003) Saisho, H. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol 38: 573–578.
76. Kanzler S. Gerken G. Dienes H. Meyer zum Buschenfelde K. Lohse A. (1997) Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis – report of three cases. Z Gastroenterol 35: 571–578.
77. Kaplan M. Alling D. Zimmerman H. Wolfe H. Sepersky R. Hirsch G. et al. (1986) A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 315: 1448–1454.
78. Kaplan M. Cheng S. Price L. Bonis P. (2004) A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology 39: 915–923.
79. Kirk A. Jain S. Pocock S. Thomas H. Sherlock S. (1980) Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 21: 78–93.
80. Kita R. Kita-Sasai Y. Hanaoka I. Kimura T. Kokuryu H. Takamatsu S. et al. (2002) Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports). Am J Gastroenterol 97: 1849–1851.
81. Kogan J. Safadi R. Ashur Y. Shouval D. Ilan Y. (2002) Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 35: 75–81.
82. Kowdley K. Jones D. Luketic V. Chapman R. Burroughs A. Hirschfield G. et al. (2011) An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC [abstract]. J Hepatol 54(Suppl.): S13.
83. Kremer A. Oude Elferink R. Beuers U. (2011) Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol 35: 89–97.
84. Kumagi T. Guindi M. Fischer S. Arenovich T. Abdalian R. Coltescu C. et al. (2010) Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 105: 2186–2194.
85. Kurihara T. Maeda A. Shigemoto M. Yamashita K. Hashimoto E. (2002) Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. Am J Gastroenterol 97: 212–214.
86. Lankisch T. Metzger J. Negm A. Vosskuhl K. Schiffer E. Siwy J. et al. (2011) Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 53: 875–884.
87. Larsen F. Vainer B. Eefsen M. Bjerring P. Hansen B. (2007) Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 13: 3232–3236.
88. Lee J. Belanger A. Joucette J. Stanca C. Friedman S. Bach N. (2007) Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 5: 1313–1315.
89. Leung J. Bonis P. Kaplan M. (2011) Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 9: 776–780.
90. Leuschner M. Maier K. Schlichting J. Strahl S. Herrmann G. Dahm H. et al. (1999) Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 117: 918–925.
91. Levy C. Peter J. Nelson D. Keach J. Petz J. Cabrera R. et al. (2011) Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 33: 235–242.
92. Levy C. Zein C. Gomez J. Soldevila-Pico C. Firpi R. Morelli G. et al. (2007) Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 5: 803–808.
93. Liaskou E. Karikoski M. Reynolds G. Lalor P. Weston C. Pullen N. et al. (2011) Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity. Hepatology 53: 661–672.
94. Lindor K. (1997) Ursodiol for primary sclerosing cholangitis: Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 336: 691–695.
95. Lindor K. Gershwin E. Poupon R. Kaplan M. Bergasa N. Heathcote J. (2009) AASLD practice guidelines: primary biliary cirrhosis. Hepatology 50: 291–308.
96. Lindor K. Jorgensen R. Therneau T. Malinchoc M. Dickson E. (1997) Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 72: 1137–1140.
97. Lindor K. Kowdley K. Luketic V. Harrison M. McCashland T. Befeler A. et al. (2009) High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 50: 808–814.
98. Lindor K. Therneau T. Jorgensen R. Malinchoc M. Dickson E. (1996) Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 110: 1515–1518.
99. Lindström L. Boberg K. Ingalill Friis-Liby I. Hultcrantz R. Bergquist A. (2012 a) A reduction in alkaline phosphatase levels is associated to improved prognosis in primary sclerosing cholangitis: a 14 year follow up of the Scandinavian ursodeoxycholic acid trial [abstract]. Hepatology 56(Suppl. 1): A110.
100. Lindström L. Boberg K. Wikman O. Friis-Liby I. Hultcrantz R. Prytz H. et al. (2012 b) High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther 35: 451–457.
101. Lleo A. Gershwin M. Mantovani A. Invernizzi P. (2012) Towards common denominators in primary biliary cirrhosis: the role of IL-12. J Hepatol 256:731–733.
102. Locke G. Therneau T. Ludwig J. Dickson E. Lindor K. (1996) Time course of histological progression in primary biliary cirrhosis. Hepatology 23: 52–56.
103. Lohse A. Mieli-Vergani G. (2011) Autoimmune hepatitis. J Hepatol 55: 171–182.
104. Lombard M. Portmann B. Neuberger J. Williams R. Tygstrup N. Ranek L. et al. (1993) Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 104: 519–526.
105. Longhi M. Hussain M. Bogdanos D. Quaglia A. Mieli-Vergani G. Ma Y. et al. (2007) Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 46: 472–484.
106. Longhi M. Hussain M. Kwok W. Mieli-Vergani G. Ma Y. Vergani D. (2011) Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology 53: 536–547.
107. Longhi M. Ma Y. Bogdanos D. Cheeseman P. Mieli-Vergani G. Vergani D. (2004) Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 41: 31–37.
108. Lüth S. Herkel J. Kanzler S. Frenzel C. Galle P. Dienes H. et al. (2008) Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol 42: 926–930.
109. Manns M. Czaja A. Gorham J. Krawitt E. Mieli-Vergani G. Vergani D. et al. (2010 a) Diagnosis and management of autoimmune hepatitis. Hepatology 51: 2193–2213.
110. Manns M. Woynarowski M. Kreisel W. Lurie Y. Rust C. Zuckerman E. et al. (2010 b) Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 139: 1198–1206.
111. Martin C. Blanco P. Keach J. Petz J. Zaman M. Bhaskar K. et al. (2012) The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther 35: 255–265.
112. Mason A. (2011) The evidence supports a viral aetiology for primary biliary cirrhosis. J Hepatol 54: 1312–1314.
113. Mason A. Farr G. Xu L. Hubscher S. Neuberger J. (2004) Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastroenterol 99: 2348–2355.
114. Mason A. Lindor K. Bacon B. Vincent C. Neuberger J. Wasilenko S. (2008) Clinical trial: randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther 28: 886–894.
115. Mason A. Luketic V. Lindor K. Hirschfield G. Gordon S. Mayo M. et al. (2010) Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of INT-747 to ursodeoxycholic acid [abstract]. J Hepatol 4(Suppl.): S1–S2.
116. Mederacke I. Helfritz F. Puls F. Ringe K. Klempnauer J. Manns M. et al. (2012) Budd-Chiari syndrome after treatment with budesonide in a cirrhotic patient with autoimmune hepatitis. Ann Hepatol 11: 143–144.
117. Mells G. Floyd J. Morley K. Cordell H. Franklin C. Shin S. et al. (2011) Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 43: 329–332.
118. Metzger J. Negm A. Plentz R. Weismüller T. Wedemeyer J. Karlsen T. et al. (2013) Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut 62: 122–130.
119. Mitchell S. Bansi D. Hunt N. von Bergmann K. Fleming K. Chapman R. (2001) A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121: 900–907.
120. Mitchison H. Palmer J. Bassendine M. Watson A. Record C. James O. (1992) A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 15: 336–344.
121. Modica S. Petruzzelli M. Bellafante E. Murzilli S. Salvatore L. Celli N. et al. (2012) Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 142: 355–365.
122. Montano-Loza A. Carpenter H. Czaja A. (2007 a) Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 27: 507–515.
123. Montano-Loza A. Carpenter H. Czaja A. (2007 b) Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 46: 1138–1145.
124. Montano-Loza A. Carpenter H. Czaja A. (2007 c) Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastrol 102: 1005–1012.
125. Murray-Lyon I. Stern R. Williams R. (1973) Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1: 735–737.
126. Neuberger J. Gunson B. Hubscher S. Nightingale P. (2004) Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 10: 488–491.
127. O‘Brien C. Senior J. Arora-Mirchandani R. Batta A. Salen G. (1991) Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 14: 838–847.
128. Ohira H. Sato Y. Ueno T. Sata M. (2002) Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol 97: 2147–2149.
129. Olsson R. Boberg K. de Muckadell O. Lindgren S. Hultcrantz R. Folvik G. et al. (2005) High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 129: 1464–1472.
130. Pardi D. Loftus Loftus E. Jr Kremers W. Keach J. Lindor K. (2003) Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124: 889–893.
131. Parés A. Caballería L. Rodés J. (2006) Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 130: 715–720.
132. Patsenker E. Schneider V. Ledermann M. Saegesser H. Dorn C. Hellerbrand C. et al. (2011) Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol 55: 388–398.
133. Peiseler M. Sebode M. Franke B. Wortmann F. Schwinge D. Quaas A. et al. (2012) FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol 57: 125–132.
134. Ponsioen C. Vrouenraets M. Prawirodirdjo W. Rajaram R. Rauws E. Mulder C. et al. (2002) Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 51: 562–566.
135. Poropat G. Giljaca V. Stimac D. Gluud C. (2011) Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev (1): CD003626.
136. Poupon R. (2011) Treatment of primary biliary cirrhosis with ursodeoxycholic acid, budesonide and fibrates. Dig Dis 29: 85–88.
137. Pratt D. Flavin D. Kaplan M. (1996) The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 110: 271–274.
138. Prince M. Chetwynd A. Newman W. Metcalf J. James O. (2002) Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 123: 1044–1051.
139. Rabahi N. Chrétien Y. Gaouar F. Wendum D. Serfaty L. Chazouillères O. et al. (2010) Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol 34: 283–287.
140. Rautiainen H. Kärkkäinen P. Karvonen A. Nurmi H. Pikkarainen P. Nuutinen H. et al. (2005) Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 41: 747–752.
141. Richardson P. James P. Ryder S. (2000) Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 33: 371–375.
142. Rudolph G. Gotthardt D. Kloeters-Plachky P. Rost D. Kulaksiz H. Stiehl A. (2010) In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol 53: 313–317.
143. Rudolph G. Kloeters-Plachky P. Rost D. Steihl A. (2007) The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol 19: 487–491.
144. Sandborn W. Feagan B. Fedorak R. Scherl E. Fleisher M. Katz S. et al. (2008) A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135: 1130–1141.
145. Santos E. Arosemena L. Raez L. O'Brien C. Regev A. (2006) Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int 26: 625–629.
146. Schalm S. Korman M. Summerskill W. Czaja A. Baggenstoss A. (1977) Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis 22: 973–980.
147. Schramm C. Weiler-Normann C. Wiegard C. Hellweg S. Müller S. Lohse A. (2010) Treatment response in patients with autoimmune hepatitis. Hepatology 52: 2247–2248.
148. Sciveres M. Caprai S. Palla G. Ughi C. Maggiore G. (2004) Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents. Aliment Pharmacol Ther 19: 209–217.
149. Sherman K. Narkewicz M. Pinto P. (1994) Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 21: 1040–1047.
150. Silveira M. Torok N. Gossard A. Keach J. Jorgensen R. Petz J. et al. (2009) Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol 104: 83–88.
151. Sockalingam S. Blank D. Abdelhamid N. Abbey S. Hirschfield G. (2012) Identifying opportunities to improve management of autoimmune hepatitis: evaluation of drug adherence and psychosocial factors. J Hepatol 57: 1299–1304.
152. Stanich P. Björnsson E. Gossard A. Enders F. Jorgensen R. Lindor K. (2011) Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis 43: 309–313.
153. Stellon A.J. Keating J.J. Johnson P.J. McFarlane I.G. Williams R. (1988) Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 8 (4): 781–784.
154. Stiehl A. Walker S. Stiehl L. Rudolph G. Hofmann W. Theilmann L. (1994) Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 20: 57–64.
155. Subramaniam K. Chitturi S. Brown M. Pavli P. (2011) Infliximab-induced autoimmune hepatitis in Crohn's disease treated with budesonide and mycophenolate. Inflamm Bowel Dis 17: E149–E150.
156. Tannous M. Cheng J. Muniyappa K. Farooq I. Bharara A. Kappus M. et al. (2011) Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther 34: 405–407.
157. Tischendorf J. Hecker H. Kruger M. Manns M. Meier P. (2007) Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 102: 107–114.
158. Triantos C. Koukias N. Nikolopoulou V. Burroughs A. (2011) Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther 34: 901–910.
159. Trivedi P. Chapman R. (2012) PSC, AIH and overlap syndrome in inflammatory bowel disease. Clin Res Hepatol Gastroenterol 36: 420–436.
160. Trivedi P. Cullen S. (2012) Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments. Hepatol Int [Epub ahead of print]. doi: 10.1007/s12072-012-9362-7
161. Trivedi P. Hirschfield G. (2012) Review article: Overlap syndromes associated with autoimmune liver disease. Alim Pharm Ther 36: 517–533.
162. Tsai S. Pawlik T. (2009) Primary sclerosing cholangitis: the role of extrahepatic biliary resection. Adv Surg 43: 175–188.
163. Tsuda M. Moritoki Y. Lian Z. Zhang W. Yoshida K. Wakabayashi K. et al. (2012) Biochemical and immunologic effects of rituximab in primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid. Hepatology 55: 512–521.
164. van Gerven N. Verwer B. Witte B. van Hoek B. Coenraad M. van Erpecum K. et al. (2013) Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol 58: 141–147.
165. van Hoogstraten H. Wolfhagen F. van de Meeberg P. Kuiper H. Nix G. Becx M. et al. (1998) Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single vs. multiple daily doses. J Hepatol 29: 417–423.
166. Verma S. Gunuwan B. Mendler M. Govindrajan S. Redeker A. (2004) Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 99: 1510–1516.
167. Vleggaar F. van Buuren H. Zondervan P. ten Kate F. Hop W. (2001) Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant. Gut 49: 276–281.
168. Vuoristo M. Farkkila M. Karvonen A. Leino R. Lehtola J. Mäkinen J. et al. (1995) A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology 108: 1470–1478.
169. Wang Q. Qiu D. Ma X. (2011) Early normalisation of aminotransferase predicts complete biochemical remission in autoimmune hepatitis patients. Aliment Pharmacol Ther 34: 107–109.
170. Webster G. Pereira S. Chapman R. (2009) Autoimmune pancreatitis/IgG4-associated cholangitis and primary sclerosing cholangitis – overlapping or separate diseases? J Hepatol 51: 398–402.
171. Weiler-Normann C. Schramm C. Quaas A. Wiegard C. Glaubke C. Pannicke N. et al. (2012) Infliximab as a rescue-treatment in difficult-to-treat autoimmune hepatitis. J Hepatol 21 November [Epub ahead of print].
172. Wiesner R. Ludwig J. Lindor K. Jorgensen R. Baldus W. Homburger H. et al. (1990) A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med 322: 1419–1424.
173. Wolf J. Rybicki L. Lashner B. (2005) The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 22: 783–788.
174. Wolfhagen F. van Hoogstraten H. van Buuren H. van Berge-Henegouwen G. ten Kate F. Hop W. et al. (1998) Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study. J Hepatol 29: 736–742.
175. Yano K. Kato H. Morita S. Takahara O. Ishibashi H. Furukawa R. (2002) Is bezafibrate Histologically effective for primary biliary cirrhosis? Am J Gastroenterol 97: 1075–1077.
176. Yeoman A. Westbrook R. Zen Y. Maninchedda P. Portmann B. Devlin J. et al. (2011) Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 53: 926–934.
177. Yoshida K. Yang G. Zhang W. Tsuda M. Tsuneyama K. Moritoki Y. et al. (2009) Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology 50: 1494–1500.
178. Yoshizawa K. Matsumoto A. Ichijo T. Umemura T. Joshita S. Komatsu M. et al. (2012) Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology 56: 668–676.
179. Ytting H. Larsen F. (2011) Everolimus treatment of severe autoimmune hepatitis [abstract]. Hepatology 54(Suppl. 1): 229A.
180. Zachou K. Gatselis N. Papadamou G. Rigopoulou E. Dalekos G. (2011) Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol 55: 636–646.
181. Zhang W. Fei Y. Gao J. Liu B. Zhang F. (2011) The role of CXCR 3 in the induction of primary biliary cirrhosis. Clin Dev Immunol 2011: 564062.